search
Back to results

A Trial of Functional Remediation in Patients With Bipolar Disorder

Primary Purpose

Bipolar Disorder

Status
Unknown status
Phase
Not Applicable
Locations
Italy
Study Type
Interventional
Intervention
Functional Remediation
Treatment as usual
Sponsored by
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Bipolar Disorder focused on measuring Bipolar Disorder, Psychosocial Functioning, Functional Remediation, Mood Disorder, Cognitive Enhancement, Cognitive Dysfunctions, Psychosocial interventions, Cognitive Remediation

Eligibility Criteria

18 Years - 55 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients with a clinical diagnosis of Bipolar Disorder, type I or II, as referred from treating psychiatrist, confirmed at recruitment using the Structured Clinical Interview for Disorder for DSM-5, Clinical Version (SCID-5-CV);
  • Clinically stable (in euthymic phase, defined as Y-MRS <= 6 points + HAM-D <= 8 points) for at least 2 months;
  • Aged from 18 to 55 years, with no restriction in terms of gender or ethnicity
  • With a minimum education level of 8 years;
  • Fluent in Italian language;
  • Giving written informed consent to study participation.

Exclusion Criteria:

  • Intellectual disability (according to DSM-5 criteria);
  • Any medical condition that may affect neuropsychological performance (such as neurological diseases);
  • Any comorbid psychiatric condition (including current alcohol and/or drug abuse - up to 3 months before screening)
  • Pregnancy;
  • Inability to provide informed consent/ withdrawal of consent.

Sites / Locations

  • Department of Mental Health and Addiction Services

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Other

Arm Label

Functional Remediation

Control

Arm Description

Functional Remediation

Treatment as usual

Outcomes

Primary Outcome Measures

Psychosocial functioning
Functional outcome will be rated using the Functioning Assessment Short Test (FAST) - Italian Version (Barbato et al., 2013)
Psychosocial functioning
Functional outcome will be rated using the Functioning Assessment Short Test (FAST) - Italian Version (Barbato et al., 2013)

Secondary Outcome Measures

Neurocognitive performance
Neurocognitive performance will be tested using a complete neuropsychological battery specifically developed for patients with bipolar disorder: the Brief Assessment of Cognition in Affective Disorders (BAC-A) (Keefe et al., 2014), Italian normative data (Rossetti et al. 2019)
Neurocognitive performance
Neurocognitive performance will be tested using a complete neuropsychological battery specifically developed for patients with bipolar disorder: the Brief Assessment of Cognition in Affective Disorders (BAC-A) (Keefe et al., 2014), Italian normative data (Rossetti et al. 2019)
Socio-cognitive performance/Emotional processing
Social cognition will be evaluated using the Mayer-Salovey-Caruso Emotional Intelligence Test (MSCEIT), Italian version (Curci et al, 2003)
Socio-cognitive performance/Emotional processing
Social cognition will be evaluated using the Mayer-Salovey-Caruso Emotional Intelligence Test (MSCEIT), Italian version (Curci et al, 2003)
Subthreshold manic symptoms
Manic symptoms will be evaluated using the Young Mania Rating Scale (Y-MRS) (Young et al, 1978). Euthymia will be defined by a score of Y-MRS <= 6 points.
Subthreshold manic symptoms
Manic symptoms will be evaluated using the Young Mania Rating Scale (Y-MRS) (Young et al, 1978). Euthymia will be defined by a score of Y-MRS <= 6 points.
Subthreshold depressive symptoms
Depressive symptoms will be evaluated using the Hamilton Depression Rating Scale (HAM-D) (Hamilton et al, 1960). Euthymia will be defined by a score of HAM-D <= 8 points.
Subthreshold depressive symptoms
Depressive symptoms will be evaluated using the Hamilton Depression Rating Scale (HAM-D) (Hamilton et al, 1960). Euthymia will be defined by a score of HAM-D <= 8 points.

Full Information

First Posted
September 30, 2020
Last Updated
September 30, 2020
Sponsor
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
search

1. Study Identification

Unique Protocol Identification Number
NCT04577508
Brief Title
A Trial of Functional Remediation in Patients With Bipolar Disorder
Official Title
Efficacy of Functional Remediation on Cognitive and Psychosocial Functioning in Patients With Bipolar Disorder: a Randomized Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
September 2020
Overall Recruitment Status
Unknown status
Study Start Date
January 2021 (Anticipated)
Primary Completion Date
June 2023 (Anticipated)
Study Completion Date
June 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
In the last decade several evidences show that cognitive impairment is a major feature of bipolar disorder (BD), that is strongly associated with patients' functional outcome. The most affected cognitive domains in BD are attention, memory and executive functions. BD represents a mental illness of considerable therapeutic complexity and the fight against cognitive and functional deterioration have contributed to increase the interest in the development of specific therapeutic strategies.There is the need of new non-pharmacological interventions in BD in order to improve not only affective symptoms, but also cognitive dysfunctions, with the final goal to achieve full functional recovery. The present study is focused on Functional Remediation (FR), a novel group intervention created by the Bipolar Disorder Unit of the Hospital Clinic of Barcelona and designed specifically for bipolar patients, based on a neuro-cognitive-behavioural approach. It involves neurocognitive and psychoeducation techniques (21 weekly sessions). The present study aims to assess FR efficacy in improving cognitive deficits and psychosocial functioning in a sample of euthymic patients with BD, compared to standard treatment (TAU). This is a randomized and rater-blind trial, involving 54 adult out-patients diagnosed with BD I or II (DSM-5 criteria) and clinically stable for at least two months. Patients will be assessed at baseline, post-treatment and 6-months follow-up, on validated cognitive, clinical and functional rating scales. The main result expected is that patients receiving FR will show better cognitive and psychosocial performance, further confirming the preliminary evidence on the utility of FR as an element of standard care for BD patients.
Detailed Description
The main objective of this randomized, rater-blind controlled trial is to evaluate the efficacy of Functional Remediation (FR) in improving functional, clinical and cognitive outcomes in euthymic and clinically stable patients with Bipolar Disorder. FR is a novel group-based intervention, based on a neurocognitive-behavioural approach, making use of ecological techniques, specifically developed for patients with Bipolar Disorder and aimed at restoring psychosocial functioning in this population. The study will involve subjects recruited from outpatient clinics (residential or semi-residential care) within the Department of Mental Health and Addiction Services of ASST Spedali Civili, Brescia, Italy. Study participants will be assigned via central randomization to either FR or treatment as usual, the latter consisting of evidence-based drug treatment and case management. Pharmacological treatment will be maintained stable during the course of the trial, but no restriction will be applied in terms of access to evidence-based non-pharmacological interventions. Efficacy of the study intervention (lasting 6 months) will be assessed at post-treatment, and later investigated at 6-months follow-up. The study will be conducted in accordance with the ethical principles of the Declaration of Helsinki and Good Clinical Practice. It will take place within an experimental project related to the "PhD Course in Biomedical Sciences and Translational Medicine", curriculum "Neuroscience" of the University of Brescia, Italy.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Bipolar Disorder
Keywords
Bipolar Disorder, Psychosocial Functioning, Functional Remediation, Mood Disorder, Cognitive Enhancement, Cognitive Dysfunctions, Psychosocial interventions, Cognitive Remediation

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
1:1 randomization
Masking
InvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
54 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Functional Remediation
Arm Type
Experimental
Arm Description
Functional Remediation
Arm Title
Control
Arm Type
Other
Arm Description
Treatment as usual
Intervention Type
Behavioral
Intervention Name(s)
Functional Remediation
Intervention Description
Functional Remediation is a manualized, group-based psychosocial intervention built on a neurocognitive-behavioural approach, involving modeling techniques, role-playing tasks, self-instruction, positive reinforcement and metacognitive cues (Vieta E et al, Cambridge University Press, 2014). It consists of 21 90-min weekly sessions, in which a trained therapist and co-therapist work with 10-12 patients: the first 3 sessions are dedicated to psychoeducation on neurocognitive deficits; then 13 sessions of neurocognitive training sequentially target attention, memory and executive functions domains, comprising exercises carried out individually, in pairs or in small groups; the last 5 sessions focus on skills training (communication, interpersonal relationships, autonomy, stress management). Content of the sessions involves ecological tasks adapted to real-world situations, and to-be-performed in two contexts (clinical and daily). Homework is assigned, collected and discussed each time.
Intervention Type
Other
Intervention Name(s)
Treatment as usual
Intervention Description
Standard care for bipolar disorders according to good clinical practice, including drug therapy and individual case management.
Primary Outcome Measure Information:
Title
Psychosocial functioning
Description
Functional outcome will be rated using the Functioning Assessment Short Test (FAST) - Italian Version (Barbato et al., 2013)
Time Frame
Baseline to post-treatment (6 months)
Title
Psychosocial functioning
Description
Functional outcome will be rated using the Functioning Assessment Short Test (FAST) - Italian Version (Barbato et al., 2013)
Time Frame
Baseline to follow-up (12 months)
Secondary Outcome Measure Information:
Title
Neurocognitive performance
Description
Neurocognitive performance will be tested using a complete neuropsychological battery specifically developed for patients with bipolar disorder: the Brief Assessment of Cognition in Affective Disorders (BAC-A) (Keefe et al., 2014), Italian normative data (Rossetti et al. 2019)
Time Frame
Baseline to post-treatment (6 months)
Title
Neurocognitive performance
Description
Neurocognitive performance will be tested using a complete neuropsychological battery specifically developed for patients with bipolar disorder: the Brief Assessment of Cognition in Affective Disorders (BAC-A) (Keefe et al., 2014), Italian normative data (Rossetti et al. 2019)
Time Frame
Baseline to follow-up (12 months)
Title
Socio-cognitive performance/Emotional processing
Description
Social cognition will be evaluated using the Mayer-Salovey-Caruso Emotional Intelligence Test (MSCEIT), Italian version (Curci et al, 2003)
Time Frame
Baseline to post-treatment (6 months)
Title
Socio-cognitive performance/Emotional processing
Description
Social cognition will be evaluated using the Mayer-Salovey-Caruso Emotional Intelligence Test (MSCEIT), Italian version (Curci et al, 2003)
Time Frame
Baseline to follow-up (12 months)
Title
Subthreshold manic symptoms
Description
Manic symptoms will be evaluated using the Young Mania Rating Scale (Y-MRS) (Young et al, 1978). Euthymia will be defined by a score of Y-MRS <= 6 points.
Time Frame
Baseline to post-treatment (6 months)
Title
Subthreshold manic symptoms
Description
Manic symptoms will be evaluated using the Young Mania Rating Scale (Y-MRS) (Young et al, 1978). Euthymia will be defined by a score of Y-MRS <= 6 points.
Time Frame
Baseline to follow-up (12 months)
Title
Subthreshold depressive symptoms
Description
Depressive symptoms will be evaluated using the Hamilton Depression Rating Scale (HAM-D) (Hamilton et al, 1960). Euthymia will be defined by a score of HAM-D <= 8 points.
Time Frame
Baseline to post-treatment (6 months)
Title
Subthreshold depressive symptoms
Description
Depressive symptoms will be evaluated using the Hamilton Depression Rating Scale (HAM-D) (Hamilton et al, 1960). Euthymia will be defined by a score of HAM-D <= 8 points.
Time Frame
Baseline to follow-up (12 months)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients with a clinical diagnosis of Bipolar Disorder, type I or II, as referred from treating psychiatrist, confirmed at recruitment using the Structured Clinical Interview for Disorder for DSM-5, Clinical Version (SCID-5-CV); Clinically stable (in euthymic phase, defined as Y-MRS <= 6 points + HAM-D <= 8 points) for at least 2 months; Aged from 18 to 55 years, with no restriction in terms of gender or ethnicity With a minimum education level of 8 years; Fluent in Italian language; Giving written informed consent to study participation. Exclusion Criteria: Intellectual disability (according to DSM-5 criteria); Any medical condition that may affect neuropsychological performance (such as neurological diseases); Any comorbid psychiatric condition (including current alcohol and/or drug abuse - up to 3 months before screening) Pregnancy; Inability to provide informed consent/ withdrawal of consent.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Antonio Vita, Prof
Phone
+39 0303995233
Email
antonio.vita@unibs.it
First Name & Middle Initial & Last Name or Official Title & Degree
Vivian Accardo, Psy
Phone
+39 3474892946
Email
v.accardo@unibs.it
Facility Information:
Facility Name
Department of Mental Health and Addiction Services
City
Brescia
State/Province
BS
ZIP/Postal Code
25133
Country
Italy
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Vivian Accardo, Psy
Phone
+39 3474892946
Email
v.accardo@unibs.it

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

A Trial of Functional Remediation in Patients With Bipolar Disorder

We'll reach out to this number within 24 hrs